Torisel, Orencia and Forteo price-listed and set for launch in Japan
This article was originally published in Scrip
Executive Summary
Several important new therapies have received a reimbursement price in Japan, including Pfizer's kidney cancer drug Torisel (temsirolimus), Bristol-Myers Squibb's Orencia (abatacept) for rheumatoid arthritis and Lilly's Forteo (teriparatide) for osteoporosis.